Inducible Nitric Oxide Synthase Promoter Polymorphism, Cigarette Smoking, and Urothelial Carcinoma Risk

Shen, Cheng; Wang, Yuan Hung; Wang, Wen Chuang; Jou, Yeong Chin; Hsu, Hueih Shing; Hsieh, He-Yen; Chiou, Hung Yi

doi:10.1016/j.urology.2007.02.028

Cited by 18 publications

(12 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A slightly (20%) higher risk of asbestosis for the iNOS LL genotype compared to the combined SL and SS genotypes and almost 30% for the LL versus SL genotype has been detected. This finding, although borderline significant, could be in agreement with the observations of some other studies which demonstrated an association between a disease and longer forms of (CCTTT) n repeat in the iNOS promoter region [18, 20, 21]. These results could be explained by a higher promoter activity of the iNOS gene which has been shown to increase with the (CCTTT) n repeat number in an in vitro study [19] and consequently increased production of NO.…”

Section: Discussionsupporting

confidence: 93%

“…The CCTTT pentanucleotide repeats within the promotor region of the human iNOS gene have been associated with the biochemical promoter activity [19]. Several studies have suggested an association between inflammatory diseases or cancer and the number of the CCTTT repeats [18–21]. However, to our knowledge and according to the literature available, this polymorphism has not been studied so far in association with asbestosis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Inducible Nitric Oxide Synthase Genetic Polymorphism and Risk of Asbestosis

Franko

Dodic-Fikfak

Arnerić

et al. 2011

BioMed Research International

View full text Add to dashboard Cite

Asbestos, a known occupational pollutant, may upregulate the activity of inducible nitric oxide synthase (iNOS) and thus the production of nitric oxide (NO). This study investigated whether iNOS (CCTTT)n polymorphism is associated with an increased asbestosis risk in exposed workers. The study cohort consisted of 262 cases with asbestosis and 265 controls with no asbestos-related disease. For each subject the cumulative asbestos exposure data were available. The number of CCTTT repeats was determined following PCR amplification of the iNOS promoter region. Logistic regression was performed to estimate asbestosis risk. The OR of asbestosis was 1.20 (95% CI = 0.85–1.69) for the LL genotype compared to the combined SL and SS genotypes and 1.26 (95% CI = 0.86–1.85) for the LL genotype compared to the SL genotype. The results of this study are borderline significant and suggest a possible role of iNOS (CCTTT)n polymorphism in the risk of asbestosis; however, further studies are needed.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Inducible Nitric Oxide Synthase Genetic Polymorphism and Risk of Asbestosis

Franko

Dodic-Fikfak

Arnerić

et al. 2011

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…NOS inhibition enhanced the antitumor effect of radiation in the treatment of squamous carcinoma xenografts 258. NOS polymorphisms were reported to be associated with bladder cancer,259 urothelial carcinoma,260 gastric cancer,261 colorectal cancer,262 and non-Hodgkin’s lymphoma 263. In a meta-analysis, endothelial NOS 894G > T polymorphism was associated with breast cancer 264.…”

Section: The Role Of β-Adrenergic Blockers In Cancermentioning

confidence: 99%

The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms

Lương

Nguyễn²

2012

CMAR

View full text Add to dashboard Cite

Cancer is the leading cause of death in the USA, and the incidence of cancer increases dramatically with age. Beta-adrenergic blockers appear to have a beneficial clinical effect in cancer patients. In this paper, we review the evidence of an association between β-adrenergic blockade and cancer. Genetic studies have provided the opportunity to determine which proteins link β-adrenergic blockade to cancer pathology. In particular, this link involves the major histocompatibility complex class II molecules, the renin–angiotensin system, transcription factor nuclear factor-kappa-light-chain-enhancer of activated B cells, poly(ADP-ribose) polymerase-1, vascular endothelial growth factor, and the reduced form of nicotinamide adenine dinucleotide phosphate oxidase. Beta-adrenergic blockers also exert anticancer effects through non-genomic factors, including matrix metalloproteinase, mitogen-activated protein kinase pathways, prostaglandins, cyclooxygenase-2, oxidative stress, and nitric oxide synthase. In conclusion, β-adrenergic blockade may play a beneficial role in cancer treatment. Additional investigations that examine β-adrenergic blockers as cancer therapeutics are required to further elucidate this role.

show abstract

“…Bladder cancer is the second most common malignancy of the genitourinary tract and it is the eighth most commonly malignancy among men in Taiwan [5]. Previous studies have reported that increased survivin expression was associated with various cancers including bladder, colorectal, lung and oral [6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

<i>Survivin</i> promoter rs9904341 polymorphism is associated with tumor stage and grade in patients with bladder cancer

Huang¹,

Chiang²,

Tung³

et al. 2013

ABB

Self Cite

View full text Add to dashboard Cite

show abstract

Inducible Nitric Oxide Synthase Promoter Polymorphism, Cigarette Smoking, and Urothelial Carcinoma Risk

Cited by 18 publications

References 27 publications

Inducible Nitric Oxide Synthase Genetic Polymorphism and Risk of Asbestosis

Inducible Nitric Oxide Synthase Genetic Polymorphism and Risk of Asbestosis

The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms

<i>Survivin</i> promoter rs9904341 polymorphism is associated with tumor stage and grade in patients with bladder cancer

Contact Info

Product

Resources

About

Inducible Nitric Oxide Synthase Promoter Polymorphism, Cigarette Smoking, and Urothelial Carcinoma Risk

Cited by 18 publications

References 27 publications

Inducible Nitric Oxide Synthase Genetic Polymorphism and Risk of Asbestosis

Inducible Nitric Oxide Synthase Genetic Polymorphism and Risk of Asbestosis

The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms

&lt;i&gt;Survivin&lt;/i&gt; promoter rs9904341 polymorphism is associated with tumor stage and grade in patients with bladder cancer

Contact Info

Product

Resources

About

<i>Survivin</i> promoter rs9904341 polymorphism is associated with tumor stage and grade in patients with bladder cancer